Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GB226 in PD-L1-positive recurrent or metastatic cervical cancer after platinum failure
CTR20190423Phase 2Active
- Sponsor
- Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of geptanolimab in Cervical Cancer (CC), sponsored by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology. Started May 2019; status: active.
02
Drugs
geptanolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20190423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190423.